{"analyses":[{"ciLowerLimit":"0.644","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.029","estimateComment":"Assuming proportional hazards, a hazard ratio less than 1 indicates a reduction in hazard rate in favor of palbociclib plus fulvestrant.","groupDescription":"The primary hypothesis to be tested was H0: λ≥1 versus. HA: λ\\<1, where λ was the palbociclib plus fulvestrant: placebo plus fulvestrant hazard ratio (HR). A HR less than 1 indicates a reduction in hazard rate in favor of Palbociclib + Fulvestrant. The study was planned to have 90% power and control the type-I error rate at 0.025.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"=0.0429","pValueComment":"1-sided p-value from the log-rank test stratified by the presence of visceral metastases and sensitivity to prior endocrine therapy per randomization.","paramType":"Hazard Ratio (HR)","paramValue":"0.814","statisticalComment":"The log rank test stratified by sensitivity to prior hormonal therapy and the presence of visceral metastases based on the randomization information.","statisticalMethod":"Stratified Log Rank Test (1-sided)"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"28.8","upperLimit":"40.0","value":"34.9"},{"groupId":"OG001","lowerLimit":"23.6","upperLimit":"34.6","value":"28.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"347"},{"groupId":"OG001","value":"174"}],"units":"Participants"}],"description":"OS is defined as the time from date of randomization to date of death due to any cause. In the absence of confirmation of death, survival time was censored to last date the participant was known to be alive. For participants lacking survival data beyond the date of their last follow-up, the OS time was censored on the last date they were known to be alive. Participants lacking survival data beyond randomization were to have their OS times be censored at randomization. The length of OS was calculated as OS time (months) = \\[death date (censor date) - randomization date + 1\\]/30.4.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were administered an initial dose of 125 mg per day orally continuously for 3 weeks followed by 1 week off that can be reduced to 100 mg or 75 mg in case of toxicity; repeated at each subsequent cycle and fulvestrant 500 mg intramuscularly on days 1 and 15 of cycle 1 and then every 28 days. Pre- and perimenopausal women received goserelin at least 4 weeks before study treatment start and continued receiving concurrent ovarian function suppression with goserelin administered subcutaneously every 28 days during the active treatment phase. Maximum treatment duration was 105 cycles.","id":"OG000","title":"Palbociclib + Fulvestrant"},{"description":"Participants were administered placebo orally continuously dosed for 3 weeks followed by 1 week off; repeated at each subsequent cycle and Fulvestrant 500 mg intramuscularly on Days 1 and 15 of cycle 1 and then every 28 days. Pre- and perimenopausal women received goserelin at least 4 weeks before study treatment start and continued receiving concurrent ovarian function suppression with goserelin administered subcutaneously every 28 days during the active treatment phase. Maximum treatment duration was 93 cycles.","id":"OG001","title":"Placebo + Fulvestrant"}],"paramType":"MEDIAN","populationDescription":"The ITT population or full analysis set included all participants who were randomized, with study intervention, regardless of whether participants received the study intervention or received a different drug from that to which they were randomized.","reportingStatus":"POSTED","timeFrame":"From randomization until death (up to 4.5 years)","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}